Biosynex SA
PAR:ALBIO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.71
8.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biosynex SA
Biosynex SA
Additional Paid In Capital
Biosynex SA
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biosynex SA
PAR:ALBIO
|
Additional Paid In Capital
€25.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
15%
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biomerieux SA
PAR:BIM
|
Additional Paid In Capital
€3.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Carmat SA
PAR:ALCAR
|
Additional Paid In Capital
€31.3m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-7%
|
|
|
Visiomed Group SA
PAR:ALVMG
|
Additional Paid In Capital
€30.2m
|
CAGR 3-Years
71%
|
CAGR 5-Years
4%
|
CAGR 10-Years
27%
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Additional Paid In Capital
€146.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Biosynex SA
Glance View
Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
See Also
What is Biosynex SA's Additional Paid In Capital?
Additional Paid In Capital
25.6m
EUR
Based on the financial report for Jun 30, 2024, Biosynex SA's Additional Paid In Capital amounts to 25.6m EUR.
What is Biosynex SA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
15%
Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Biosynex SA have been -18% over the past three years , -2% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
